Team work
Two new drugs hold promise for tuberculosis patients
tuberculosis is a common and deadly disease caused by the bacterium Mycobacterium tuberculosis. It leads to 1.6 to 2 million deaths annually. Worse still, most of the bacterial strains are resistant to multiple drugs and their numbers are rising. The class of compounds called b-lactams, which also contains penicillin, is used to treat a variety of bacterial infections. But when it comes to tuberculosis it fails. Researchers have hit upon a combined dose of two compounds from the same class that shows promise in the unabated war on tuberculosis.
b-lactams work by arresting bacterial cell wall synthesis. In case of tuberculosis, the bacterial enzyme b-lactamase degrades the drugs and renders them ineffective.
Researchers from the Albert Einstein College of Medicine and the National Institutes of Health, US, have shown that a combined dose of two b-lactams
Related Content
- Further action taken report on behalf of District Magistrate, Gonda regarding determination/demarcation of the flood plain zone of Tedhi river, 04/03/2025
- Report filed by the Wadia Institute of Himalayan Geology on the massive land sinking at Pernote village in Ramban district of Jammu & Kashmir, 27/01/2025
- Roadmap for parking reforms in Indian cities
- State of global environmental governance 2023
- Uttar Pradesh Pollution Control Board report regarding illegal mining near river Ken, Banda district, 19/06/2023
- Six monthly progress report on solid waste and liquid waste management of Manipur, 16/06/2023